NovoCure Limited - Ordinary Shares (NQ:NVCR)

15.21 +0.28 (+1.84%)

Delayed Quote Updated: 12:36 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

A Closer Look at 7 Analyst Recommendations For NovoCure ↗

June 04, 2024

Via Benzinga

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

June 03, 2024

From Novocure

Via Business Wire

Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗

May 20, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 15, 2024

Via Benzinga

Unveiling 8 Analyst Insights On NovoCure ↗

May 02, 2024

Via Benzinga

Why NovoCure Stock Soared 18.3% This Week ↗

March 30, 2024

Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.

Via The Motley Fool

Why Novocure Stock Is Jumping Today ↗

March 28, 2024

Novocure had good news mixed with some not-so-good news.

Via The Motley Fool

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗

May 14, 2024

These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.

Via InvestorPlace

NovoCure (NVCR) Q1 2024 Earnings Call Transcript ↗

May 03, 2024

NVCR earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 02, 2024

From Novocure

Via Business Wire

Peeling Back The Layers: Exploring NovoCure Through Analyst Insights ↗

March 27, 2024

Via Benzinga

Novocure Reports First Quarter 2024 Financial Results

May 02, 2024

From Novocure

Via Business Wire

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

April 24, 2024

From Novocure

Via Business Wire

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

April 05, 2024

From Novocure

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

April 03, 2024

Via Benzinga

Novocure to Report First Quarter 2024 Financial Results

April 01, 2024

From Novocure

Via Business Wire

Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows ↗

March 27, 2024

Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to...

Via Benzinga

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday ↗

March 27, 2024

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

Via Benzinga

Topics Stocks

Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment ↗

March 27, 2024

The company uses electrical fields to interrupt the rampant cellular division characteristic of cancer.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 27, 2024

Via Benzinga

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 27, 2024

From Novocure

Via Business Wire

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

March 11, 2024

From Novocure

Via Business Wire

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

NovoCure (NVCR) Q4 2023 Earnings Call Transcript ↗

February 22, 2024

NVCR earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

February 22, 2024

From Novocure

Via Business Wire

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

AI Drives Tech Rebound, Oil Soars, Bitcoin Tumbles: What's Driving Markets Thursday? ↗

January 18, 2024

During midday Thursday trading in New York, U.S. stocks displayed mixed performance, with the technology sector outperforming others as investors maintained a bullish outlook on artificial...

Via Benzinga

Topics Artificial Intelligence

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 18, 2024

Via Benzinga

Why Is Cancer Focused Novocure Stock Trading Higher Today? ↗

January 18, 2024

Novocure's TTFields therapy gains FDA acceptance for non-small cell lung cancer treatment after platinum-based therapy. PMA filing under FDA review. Decision expected in 2H 2024.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.